Alnylam Pharmaceuticals Stock News

The biotech is a foot soldier in the war against Alzheimer's disease. It published encouraging interim results from a phase 1 study of its Alzheimer's treatment.

Alnylam (ALNY) reports that the FDA has set Sep 13, 2023, as the day for the meeting of the Advisory Committee to review its sNDA application for patisiran in treating the cardiomyopathy of ATTR amylo

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has set a date

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Goldman S

Biotech company Alnylam Pharmaceuticals Inc filed new lawsuits on Friday against Pfizer Inc and Moderna Inc in Delaware federal court, again claiming that the companies' COVID-19 vaccines infringe its

Alnylam (ALNY) announces positive interim analysis results from the phase III APOLLO-B study of patisiran to treat transthyretin-mediated amyloidosis with cardiomyopathy at the end of 18 months.

As 2023 unfolds, the pharmaceutical space is blossoming with new opportunities, sparking curiosity for those looking to buy some pharma stocks. With the iShares Biotechnology ETF (NASDAQ: IBB ) ticki

Avoro Capital Advisors (formerly known as venBio Select Advisor) is a global life sciences investment firm that focuses on emerging biotechnology companies.

Healthcare growth stocks are often sought out by investors looking for market disruptors. That's because these stocks can potentially deliver high revenue growth, earnings, and stock price.

Alnylam Pharmaceuticals (ALNY) reports better-than-expected fourth-quarter 2022 results. Total revenues of the company continue to be driven by the sales of Onpattro, Givlaari, Oxlumo and the newly ap

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q4 2022 Earnings Conference Call February 23, 2023 8:30 AM ET Company Participants Christine Lindenboom - Senior Vice President, Investor Relations and Cor

Alnylam (ALNY) delivered earnings and revenue surprises of 21.13% and 9.37%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Alnylam Pharmaceuticals (ALNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter a

Despite inflation making it hard for the healthcare industry to manage its operating costs, there are a few positives that make this sector attractive to investors.